SSE
Every company in the roster listed on SSE.
Every company in the roster listed on SSE.
16 of 16 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
BrightGene Bio-Medical Technology688166 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 | — | — | — | $83M |
China Resources Double-Crane Pharmaceutical600062 · SSE | 1 asset: 1 Ph 3 | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Chipscreen Biosciences688321 · SSE | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 18 Sep 2027CS32582 · Phase 1/2 | — | — | — | — |
Gan & Lee Pharmaceuticals603087 · SSE | 4 assets: 2 Ph 3, 2 Ph 2 | BofanglutidePhase 3 · ObesityPartial signal | 2 Feb 2027GZR101 · Phase 1 | — | — | — | $90M |
Hubei Jumpcan Pharmaceutical600566 · SSE | 1 asset: 1 Ph 3 | EbronucimabPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
Jiangsu Hengrui Pharmaceuticals600276 · SSE | 116 assets: 45 Ph 3, 38 Ph 2, 26 Ph 1, 7 other | ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026HRS-1780 · Phase 2 | — | $5.9BMar 2026 | — | ~$1.7B |
RemeGen Co., Ltd.688331 · SSE | 6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1 | TelitaciceptPhase 3 · Rheumatoid ArthritisReliable signal | Dec 2026Disitamab Vedotin · Phase 2/3 | — | $213MDec 2025 | — | $170M |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.600196 · SSE | 2 assets: 2 Ph 3 | AR1001Phase 3 · Alzheimer's DiseasePartial signal | 12 May 2027Velinotamig (GR1803) · Phase 2 | — | — | — | — |
| 10 assets: 2 approved, 3 Ph 3, 3 Ph 2, 2 Ph 1 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 1 Dec 2026FCN-338 · Phase 2 | — | — | — | — | |
Shanghai Pharmaceuticals Holding2607 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | SPH4336Phase 2/3 · HR+/HER2- Metastatic Breast Cancer | 1 Dec 2026SPH4336 · Phase 2/3 | — | $4.8BDec 2025 | — | $345M |
Sinocelltech Group Ltd.688520 · SSE | 3 assets: 3 Ph 3 | SCTB14Phase 3 · Non-Small Cell Lung Cancer | Apr 2027SCTC21C · Phase 1/2 | — | — | — | $118M |
Tasly Pharmaceutical Group600535 · SSE | 6 assets: 2 Ph 3, 4 Ph 2 | QiShenYiQiPhase 3 · Heart FailurePartial signal | 31 Dec 2026Jia Shen Tablet · Phase 2 | — | — | — | $118M |
Tonghua Dongbao Pharmaceutical600867 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record | — | $205MDec 2025 | — | — |
Xiamen Amoytop Biotech Co., Ltd.688278 · SSE | 1 asset: 1 Ph 1 | ACT201Phase 1 · Chronic Hepatitis B | Feb 2027ACT201 · Phase 1 | — | — | — | — |
Zhejiang Hisun Pharmaceutical600267 · SSE | 1 asset: 1 Ph 3 | HyzetimibePhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | $67M |
Zhejiang Huahai Pharmaceutical600521 · SSE | 1 asset: 1 Ph 2 | Hypidone (YL-0919)Phase 2 · Major Depressive DisorderPartial signal | None on record | — | — | — | $167M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.